OPEN-LABEL, PHASE 1 STUDY OF CD19 t-haNK AS A SINGLE AGENT AND IN COMBINATION WITH AN IL-15 SUPERAGONIST (N-803) AND RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA